Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2

Type of publication: Diagnosis, Guidelines
Disease: Myotonic dystrophy, Myotonic dystrophy type 1, Myotonic dystrophy type 2

Authors:

Erik-Jan Kamsteeg, Wolfram Kress, Claudio Catalli, Jens M Hertz, Martina Witsch-Baumgartner, Michael F Buckley, Baziel G M van Engelen, Marianne Schwartz, and Hans Scheffer


Myotonic dystrophy is an autosomal dominant, multisystem disorder that is characterized by myotonic myopathy. The symptoms and severity of myotonic dystrophy type l (DM1) ranges from severe and congenital forms, which frequently result in death because of respiratory deficiency, through to late-onset baldness and cataract. In adult patients, cardiac conduction abnormalities may occur and cause a shorter life span. In subsequent generations, the symptoms in DM1 may present at an earlier age and have a more severe course (anticipation). In myotonic dystrophy type 2 (DM2), no anticipation is described, but cardiac conduction abnormalities as in DM1 are observed and patients with DM2 additionally have muscle pain and stiffness. Both DM1 and DM2 are caused by unstable DNA repeats in untranslated regions of different genes: A (CTG)n repeat in the 3′-UTR of the DMPK gene and a (CCTG)n repeat in intron 1 of the CNBP (formerly ZNF9) gene, respectively. The length of the (CTG)n repeat expansion in DM1 correlates with disease severity and age of onset. Nevertheless, these repeat sizes have limited predictive values on individual bases. Because of the disease characteristics in DM1 and DM2, appropriate molecular testing and reporting is very important for the optimal counseling in myotonic dystrophy. Here, we describe best practice guidelines for clinical molecular genetic analysis and reporting in DM1 and DM2, including presymptomatic and prenatal testing.


Published: 30 May 2012
Journal: European Journal of Human Genetics, volume 20, pages 1203–1208

Link: doi.org/10.1038/ejhg.2012.108

This publication is recommended by the Muscle Working Group group.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern